Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Tuesday morning, Marketbeat.com reports. The firm issued a hold rating and a $136.00 price objective on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Royal Bank of Canada restated an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. HC Wainwright restated a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $176.77.

Sarepta Therapeutics Stock Performance

SRPT opened at $109.46 on Tuesday. The firm has a market capitalization of $10.46 billion, a PE ratio of 87.57 and a beta of 0.75. Sarepta Therapeutics has a twelve month low of $102.15 and a twelve month high of $173.25. The firm’s 50-day moving average price is $119.82 and its 200 day moving average price is $125.11. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Activity

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Jump Financial LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $221,000. Bridgewater Associates LP acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $638,000. Mariner LLC grew its holdings in shares of Sarepta Therapeutics by 14.8% in the fourth quarter. Mariner LLC now owns 8,042 shares of the biotechnology company’s stock valued at $978,000 after purchasing an additional 1,035 shares in the last quarter. Optimize Financial Inc acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $209,000. Finally, Kennedy Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 14.7% in the fourth quarter. Kennedy Capital Management LLC now owns 29,457 shares of the biotechnology company’s stock valued at $3,582,000 after purchasing an additional 3,776 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.